APEC1621J: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF BVD-523FB (ULIXERTINIB) IN PATIENTS WITH TUMORS HARBORING ACTIVATING MAPK PATHWAY MUTATIONS
Brief description of study
This is a phase 2 trial of BVD-523FB (ulixertinib) in children with recurrent or refractory solid tumors, CNS tumors, non-Hodgkin lymphomas and histiocytic disorders harboring specific activating mutations that result in pathologic activation of the MAPK pathway. The primary aim of this trial will be to establish the objective response rate to BVD-523FB (ulixertinib).
Clinical Study Identifier: s18-01541
ClinicalTrials.gov Identifier: NCT03698994
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
